Clinical Trials Browser

NCT07517705 2026-05-13

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

Phase 2 Not yet recruiting

50 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07572929 2026-05-07

PREeMPT

Phase 2 Not yet recruiting

450 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07392970 2026-04-09

Motixafortide for MRD Sensitization in AML

Phase 2 Not yet recruiting

10 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07507318 2026-04-02

DEL-MRD-CHID

Phase 2 Not yet recruiting

69 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07247201 2026-03-30

AlloNK1

Phase 1/2 Not yet recruiting

31 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm, Residual

NCT07443592 2026-03-02

LAL-2025

Phase NA Not yet recruiting

330 enrolled

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07413146 2026-02-17

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

Phase NA Not yet recruiting

100 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasm, Residual

NCT07350824 2026-01-20

Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC

Phase NA Not yet recruiting

276 enrolled

Recurrence, Neoplasm, Residual

NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Phase 2 Not yet recruiting

23 enrolled

LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07264010 2025-12-04

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Phase 2/3 Not yet recruiting

87 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07257380 2025-12-02

MRD-ATLAS

Phase 2 Not yet recruiting

90 enrolled

Tumor-Agnostic

Neoplasm, Residual

NCT06763302 2025-01-08

NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL

Phase NA Not yet recruiting

1,220 enrolled

Tumor-Agnostic

Neoplasm, Residual

NCT06090786 2024-04-10

Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

Phase NA Not yet recruiting

225 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06323148 2024-03-21

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Phase 3 Not yet recruiting

226 enrolled

Thoracic

Lung Neoplasms, Neoplasm, Residual

NCT05427669 2022-10-07

AFFORD

Phase 3 Not yet recruiting

340 enrolled

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual